Najat Khan Sells 28,298 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30. Following the transaction, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at approximately $7,577,984.75. This trade represents a 1.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Najat Khan also recently made the following trade(s):

• On Monday, December 22nd, Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.41, for a total value of $548,617.23.

Recursion Pharmaceuticals Trading Down 0.3%

NASDAQ:RXRX traded down $0.01 during mid-day trading on Wednesday, reaching $3.43. 14,332,931 shares of the company’s stock traded hands, compared to its average volume of 20,210,064. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.98 and a 12-month high of $7.18. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -2.32 and a beta of 0.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.50 and a quick ratio of 5.50. The company has a 50 day moving average price of $4.07 and a 200-day moving average price of $4.61.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. The business had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business’s revenue was up 671.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.53) EPS. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Bank of America cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. Vanguard Group Inc. raised its holdings in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares in the last quarter. ARK Investment Management LLC lifted its position in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after buying an additional 3,771,357 shares during the period. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after buying an additional 7,064,963 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after buying an additional 1,310,695 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $23,473,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.